Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA ’s Adverse Event Reporting System

ConclusionThese findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage.

Source: Drug Safety - February 9, 2018 Category: Drugs & Pharmacology Source Type: research